Related Experiment Video

Updated: Jun 5, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.5K

Unlocking the potential of melanotransferrin (CD228): implications for targeted drug development and novel

Yanan Zhang1, Deyong Song1, Xiaolei Han1

  • 1Research and Development Center, Shandong Boan Biotechnology Co., Ltd, Yantai, Shandong, China.

Expert Opinion on Therapeutic Targets
|December 16, 2024
PubMed
Abstract

Insights

Melanotransferrin (CD228) is a promising cancer antigen found in solid tumors. Targeting CD228 offers therapeutic potential for cancer treatment and diagnosis, with ongoing research for clinical translation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Melanotransferrin (CD228) is a cell membrane-anchored protein highly expressed in various solid tumors.
  • Its expression suggests a significant role as a cancer antigen.
  • Understanding CD228's functions is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To review the current understanding of CD228 and its isoforms.
  • To explore the therapeutic potential of targeting CD228 in oncology.
  • To summarize drug development efforts related to CD228.

Main Methods:

  • Comprehensive literature search using PubMed, Web of Science, and ClinicalTrials.gov.
  • Keywords used: 'melanotransferrin' and 'CD228'.
  • Review focused on CD228 isoforms, roles in tumorigenesis, and drug development.

Main Results:

  • CD228 has two isoforms: membrane-bound (mMFI2) and soluble (sMFI2).
  • mMFI2 is implicated in tumorigenesis, angiogenesis, and cell migration.
  • sMFI2 is relevant for diagnosing malignant tumors, Alzheimer's, arthritis, and drug delivery across the BBB.

Conclusions:

  • Targeting CD228, particularly mMFI2, presents a promising strategy for solid tumor treatment.
  • sMFI2 shows diagnostic value and potential for enhancing drug delivery.
  • Further research is needed for clinical translation of CD228-directed therapies.
Keywords:
Biological functionCD228blood-brain barrierdrug developmentmelanotransferrinoncologytherapeutic target

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K